Skip to main content
. Author manuscript; available in PMC: 2018 May 31.
Published in final edited form as: Vaccine. 2017 May 5;35(24):3239–3248. doi: 10.1016/j.vaccine.2017.04.062

Table 1. Immunization Groups.

Mice were immunized intramuscularly at day 0 with adenovirus in PBS at the dose corresponding to their group. Mice were then boosted subcutaneously at days 30 and 60 with 20 μg of the P. yoelii chimeric multistage protein (PyCMP) emulsified in Montanide ISA 51 VG in a 1:1 volume ratio. Control group mice received no immunizations. (n = 10 per group). Mice were bled for analysis of antibody titers via ELISA 20 days after each immunization. PBMCs were obtained from mouse whole blood samples at days 10, 20, 40, 50, and 70 post priming and were processed for flow cytometry.

Immunization Group Priming, Day 0 Protein Boost 1, Day 30 Protein Boost 2, Day 60
Ad-transgene Dose
SAd36 106 SAd36-PyCMP 106 v.p. PyCMP PyCMP
SAd36 107 SAd36-PyCMP 107 v.p. PyCMP PyCMP
SAd36 1010 SAd36-PyCMP 1010 v.p. PyCMP PyCMP
Ad5 107 Ad5-PyCMP 107 v.p. PyCMP PyCMP
Control No immunization No immunization No immunization